Drug Delivery Stocks List

Drug Delivery Stocks Recent News

Date Stock Title
May 9 HTGC 2 Ultra-High-Yield Stocks to Buy Hand Over Fist in May
May 9 NXGL NEXGEL to Report First Quarter 2024 Financial Results on May 13th
May 9 BDRX Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition
May 9 HTGC Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
May 9 STVN Italy Based Stevanato Reports Mixed Q1 Earnings, Revises Annual Guidance On Temporary Destocking
May 9 HTGC X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
May 9 HRTX Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Released Its First-Quarter Earnings: Here's What Analysts Think
May 8 PCRX Pacira Biosciences announces proposed offering of $250M aggregate principal amount of convertible senior notes
May 8 PCRX Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
May 8 PCRX Pacira BioSciences up 12% on stock buyback, Q1 top-line beat
May 8 HRTX Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript
May 8 PCRX Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
May 8 PCRX Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call Transcript
May 8 HRTX Heron Therapeutics First Quarter 2024 Earnings: Beats Expectations
May 8 PCRX Pacira BioSciences Inc (PCRX) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth ...
May 8 HRTX Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Call Transcript Highlights: Significant ...
May 8 PCRX Pacira BioSciences, Inc. 2024 Q1 - Results - Earnings Call Presentation
May 8 PCRX Pacira BioSciences, Inc. (PCRX) Q1 2024 Earnings Call Transcript
May 7 PCRX Pacira BioSciences Reports Q1 2024 Results: Aligns with EPS Projections and Announces $150 ...
May 7 PCRX Pacira BioSciences Non-GAAP EPS of $0.62, revenue of $167.11M
Drug Delivery

Drug delivery refers to approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect. It may involve scientific site-targeting within the body, or it might involve facilitating systemic pharmacokinetics; in any case, it is typically concerned with both quantity and duration of drug presence. Drug delivery is often approached via a drug's chemical formulation, but it may also involve medical devices or drug-device combination products. Drug delivery is a concept heavily integrated with dosage form and route of administration, the latter sometimes even being considered part of the definition.Drug delivery technologies modify drug release profile, absorption, distribution and elimination for the benefit of improving product efficacy and safety, as well as patient convenience and compliance. Drug release is from: diffusion, degradation, swelling, and affinity-based mechanisms. Some of the common routes of administration include the enteral (gastrointestinal tract), parenteral (via injections), inhalation, transdermal, topical and oral routes. . Many medications such as peptide and protein, antibody, vaccine and gene based drugs, in general may not be delivered using these routes because they might be susceptible to enzymatic degradation or can not be absorbed into the systemic circulation efficiently due to molecular size and charge issues to be therapeutically effective. For this reason many protein and peptide drugs have to be delivered by injection or a nanoneedle array.
For example, many immunizations are based on the delivery of protein drugs and are often done by injection.
Current efforts in the area of drug delivery include the development of targeted delivery in which the drug is only active in the target area of the body (for example, in cancerous tissues), sustained release formulations in which the drug is released over a period of time in a controlled manner from a formulation, and methods to increase survival of peroral agents which must pass through the stomach's acidic environment. In order to achieve efficient targeted delivery, the designed system must avoid the host's defense mechanisms and circulate to its intended site of action. Types of sustained release formulations include liposomes, drug loaded biodegradable microspheres and drug polymer conjugates. Survival of agents as they pass through the stomach typically is an issue for agents which cannot be encased in a solid tablet; one research area has been around the utilization of lipid isolates from the acid-resistant archaea Sulfolobus islandicus, which confers on the order of 10% survival of liposome-encapsulated agents.

Browse All Tags